Lombard Odier Asset Management Europe Ltd Buys Shares of 61,349 Boston Scientific Corporation $BSX

Posted by Francis Steltz on Aug 29th, 2026

Boston Scientific logo Lombard Odier Asset Management Europe Ltd bought a new position in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 61,349 shares of the medical equipment provider’s stock, valued at approximately $2,618,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in BSX. BlackRock Inc. acquired a new position in Boston Scientific during the 2nd quarter worth approximately $5,534,781,000. Primecap Management Co. CA acquired a new stake in Boston Scientific in the second quarter valued at approximately $2,156,233,000. Norges Bank acquired a new stake in Boston Scientific in the fourth quarter valued at approximately $2,199,395,000. Jupiter Topco LLC bought a new stake in shares of Boston Scientific during the second quarter worth $803,357,000. Finally, Bank of America Corp DE acquired a new position in shares of Boston Scientific during the second quarter worth $556,026,000. Institutional investors own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on BSX shares. Piper Sandler reiterated an “overweight” rating and issued a $65.00 price target on shares of Boston Scientific in a research note on Friday, June 12th. UBS Group lowered their target price on Boston Scientific from $74.00 to $67.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Stifel Nicolaus set a $60.00 target price on Boston Scientific in a research report on Wednesday, July 29th. Citigroup cut their price target on Boston Scientific from $70.00 to $61.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Finally, Zacks Research cut Boston Scientific from a “hold” rating to a “strong sell” rating in a report on Friday, June 5th. Twenty-four analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $71.62.

View Our Latest Report on BSX

Boston Scientific Trading Up 0.3%

Shares of BSX stock opened at $46.82 on Friday. The stock has a market cap of $67.85 billion, a price-to-earnings ratio of 18.96, a PEG ratio of 1.02 and a beta of 0.56. The stock has a 50-day moving average of $46.56 and a 200-day moving average of $56.65. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a 1-year low of $42.20 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX – Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same period in the previous year, the firm earned $0.75 earnings per share. The firm’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities research analysts forecast that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific declared that its Board of Directors has initiated a share repurchase plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Insider Transactions at Boston Scientific

In other news, Director Edward J. Ludwig bought 5,000 shares of the stock in a transaction that occurred on Friday, July 31st. The stock was acquired at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the purchase, the director directly owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. This represents a 19.72% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Michael F. Mahoney bought 186,240 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The stock was purchased at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the acquisition, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have bought 194,522 shares of company stock worth $9,385,210. Company insiders own 0.34% of the company’s stock.

Boston Scientific Company Profile

(Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.